Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Executive Summary
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
You may also be interested in...
Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”
Ivax will gain at least an additional 30 days of generic marketing exclusivity for Bristol-Myers Squibb's Glucophage XR after a federal judge issued a temporary restraining order blocking FDA from approving other metformin extended-release ANDAs
Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”
Ivax will gain at least an additional 30 days of generic marketing exclusivity for Bristol-Myers Squibb's Glucophage XR after a federal judge issued a temporary restraining order blocking FDA from approving other metformin extended-release ANDAs
Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus
Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics